The global genomics market size, valued at USD 38.77 billion in 2024, is expected to reach USD 46.06 billion in 2025 and USD 186.64 billion by 2035, representing a compounded annual growth rate (CAGR) of 15.0% during the forecast period. Some of the potential market drivers that are anticipated to drive the genomics market growth includes rising prevalence of cancer and growing adoption of next generation sequencing in cancer research. As per the cancer statistics published by American Cancer So...

The PARP inhibitors market is estimated to be worth $8 billion in 2030 and is expected to grow at CAGR of 18% during the forecast period. Cancer is known to be one of the leading causes of death worldwide. According to the International Agency for Research on Cancer (IARC), close to 17 million new cancer cases were reported in 2018, worldwide. By 2040, it is estimated that the aforementioned number is likely to grow to 27.5 million. Therefore, there is a pressing need for more specific and poten...

Bispecific antibodies (bsAbs) are artificial antibodies created by joining together two monoclonal antibodies (or parts) that target different epitopes.The resulting antibody has binding affinities for 2 or 3 different epitopes concurrently. Various technology platforms have been used for bsAbs production over the years. These platforms are based on the concepts of chemical crosslinking, hybrid hybridomas, with the latest being recombinant techniques. As of now, only 2 bsAbs, Removab and Blincyt...

Targeted cancer therapy is an upcoming area gaining strong foothold in the industry and has already become the focus of a number of pharmaceutical companies. Small molecule protein kinase inhibitors are a type of targeted therapy that involves small molecule drugs administered in the cancer patient for specifically targeting certain proteins, called kinases, involved in the growth of cancer cells. In fact, non-tyrosine kinase inhibitors have gradually gained attention in the last few years. Ther...

The service oriented and dynamic nature of the healthcare industry has led to the discovery of a plethora of treatment options for a wide range of ailments. Rare / orphan diseases, as the name suggests, are those diseases which are relatively infrequent in occurrence. The prevalence and adversity of these ailments has gained significant attention in the global healthcare industry. The enactment of the Orphan Drugs Act in the US and EU emerged as ground breaking and provided the necessary support...

The focus of drug developers is gradually moving towards immunotherapeutics, which make use of the body

Oral targeted therapeutics has attracted many drug developers due to the ease of administration it offers to patients (especially pediatric and geriatric patients). However, the high price of these drugs still remains a major constraint to the market growth. Further, as leukemia accounts for about 3% of all cancer cases per year, most of the companies are targeting other cancer indications offering a wider market prospective. Notably, there are specific opportunities which remain to be tapped in...